Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and maintained a price target of $10.
August 23, 2023 | 8:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verrica Pharmaceuticals has received a reiterated 'Buy' rating from Needham analyst Serge Belanger, with a maintained price target of $10.
The reiterated 'Buy' rating and maintained price target by Needham analyst Serge Belanger indicates a positive outlook for Verrica Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100